Tanya S Hauck1, Cindy Lau2, Laura Li Foa Wing2, Paul Kurdyak1,2,3,4, Karen Tu2,4,5,6. 1. 1 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 2. 2 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 3. 3 Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 4. 4 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 5. 5 Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. 6. 6 University Health Network, Toronto Western Hospital Family Health Team, Toronto, Ontario, Canada.
Abstract
BACKGROUND: The aim of this study is to determine the prevalence and characteristics of youth with attention-deficit hyperactivity disorder (ADHD) in Ontario, Canada, and to determine the predictors of psychotropic medication prescriptions in youth with ADHD. METHOD: This is a cross-sectional retrospective chart abstraction of more than 250 000 medical records from youth aged 1 to 24 years in a large geographical region in Ontario, Canada, linked to population-based health administrative data. A total of 10 000 charts were randomly selected and manually reviewed using predetermined criteria for ADHD and comorbidities. Prevalence, comorbidities, demographic indicators, and health service utilization characteristics were calculated. Predictors of treatment characteristics were determined using logistic regression modelling. RESULTS: The prevalence of ADHD was 5.4% (7.9% males, 2.7% females). Youth with ADHD had significant psychiatric comorbidities. The majority (70.0%) of ADHD patients received prescriptions for stimulant or nonstimulant ADHD medication. Antipsychotic prescriptions were provided to 11.9% of ADHD patients versus 0.9% of patients without ADHD. Antidepressant prescriptions were provided to 19.8% versus 5.4% of patients with and without ADHD, respectively. Predictors of antidepressant prescriptions were increasing age (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.07 to 1.21), psychiatric consultation (OR, 2.04; 95% CI, 1.16 to 3.58), and diagnoses of both anxiety and depression (OR, 18.4; 95% CI, 8.03 to 42.1), whereas the only predictor of antipsychotic prescriptions was psychiatric consultation (OR, 3.85; 95% CI, 2.11 to 7.02). CONCLUSIONS: Youth with ADHD have more psychiatric comorbidities than youth without ADHD. The majority of youth with ADHD received stimulant medications, and a significant number received additional psychotropic medications, with psychiatric consultation predicting medication use.
BACKGROUND: The aim of this study is to determine the prevalence and characteristics of youth with attention-deficit hyperactivity disorder (ADHD) in Ontario, Canada, and to determine the predictors of psychotropic medication prescriptions in youth with ADHD. METHOD: This is a cross-sectional retrospective chart abstraction of more than 250 000 medical records from youth aged 1 to 24 years in a large geographical region in Ontario, Canada, linked to population-based health administrative data. A total of 10 000 charts were randomly selected and manually reviewed using predetermined criteria for ADHD and comorbidities. Prevalence, comorbidities, demographic indicators, and health service utilization characteristics were calculated. Predictors of treatment characteristics were determined using logistic regression modelling. RESULTS: The prevalence of ADHD was 5.4% (7.9% males, 2.7% females). Youth with ADHD had significant psychiatric comorbidities. The majority (70.0%) of ADHDpatients received prescriptions for stimulant or nonstimulant ADHD medication. Antipsychotic prescriptions were provided to 11.9% of ADHDpatients versus 0.9% of patients without ADHD. Antidepressant prescriptions were provided to 19.8% versus 5.4% of patients with and without ADHD, respectively. Predictors of antidepressant prescriptions were increasing age (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.07 to 1.21), psychiatric consultation (OR, 2.04; 95% CI, 1.16 to 3.58), and diagnoses of both anxiety and depression (OR, 18.4; 95% CI, 8.03 to 42.1), whereas the only predictor of antipsychotic prescriptions was psychiatric consultation (OR, 3.85; 95% CI, 2.11 to 7.02). CONCLUSIONS: Youth with ADHD have more psychiatric comorbidities than youth without ADHD. The majority of youth with ADHD received stimulant medications, and a significant number received additional psychotropic medications, with psychiatric consultation predicting medication use.
Entities:
Keywords:
ADHD; antipsychotics; child and adolescent psychiatry; epidemiology; pharmacoepidemiology
Authors: Jennifer L Vande Voort; Jian-Ping He; Nicole D Jameson; Kathleen R Merikangas Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-04-23 Impact factor: 8.829
Authors: Glorisa Canino; Patrick E Shrout; Maritza Rubio-Stipec; Hector R Bird; Milagros Bravo; Rafael Ramirez; Ligia Chavez; Margarita Alegria; José J Bauermeister; Ann Hohmann; Julio Ribera; Pedro Garcia; Alfonso Martinez-Taboas Journal: Arch Gen Psychiatry Date: 2004-01
Authors: J Michael Murphy; Alyssa E McCarthy; Lee Baer; Bonnie T Zima; Michael S Jellinek Journal: Harv Rev Psychiatry Date: 2014 May-Jun Impact factor: 3.732
Authors: Karen Tu; Tezeta F Mitiku; Noah M Ivers; Helen Guo; Hong Lu; Liisa Jaakkimainen; Doug G Kavanagh; Douglas S Lee; Jack V Tu Journal: Am J Manag Care Date: 2014 Impact factor: 2.229
Authors: Charlotte Waddell; David R Offord; Cody A Shepherd; Josephine M Hua; Kimberley McEwan Journal: Can J Psychiatry Date: 2002-11 Impact factor: 4.356
Authors: Brenda M Y Leung; Peter Kellett; Erik Youngson; Josh Hathaway; Maria Santana Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2019-05-25 Impact factor: 4.328
Authors: Courtney Baker; James A Feinstein; Xuan Ma; Shari Bolen; Neal V Dawson; Negar Golchin; Alexis Horace; Lawrence C Kleinman; Sharon B Meropol; Elia M Pestana Knight; Almut G Winterstein; Paul M Bakaki Journal: Pharmacoepidemiol Drug Saf Date: 2019-02-06 Impact factor: 2.890
Authors: Jennifer D Brooks; Jasleen Arneja; Longdi Fu; Farah E Saxena; Karen Tu; Virgiliu Bogdan Pinzaru; Evdokia Anagnostou; Kirk Nylen; Natasha R Saunders; Hong Lu; John McLaughlin; Susan E Bronskill Journal: Autism Res Date: 2021-03-10 Impact factor: 5.216
Authors: Sharon B Wigal; Ann Childress; Sally A Berry; Heidi W Belden; Phillip Chappell; Dalia B Wajsbrot; Praneeta Nagraj; Richat Abbas; Donna Palumbo Journal: J Child Adolesc Psychopharmacol Date: 2018-03-13 Impact factor: 2.576
Authors: Rachael Morkem; Kenneth Handelman; John A Queenan; Richard Birtwhistle; David Barber Journal: BMC Med Inform Decis Mak Date: 2020-07-20 Impact factor: 2.796